DOCKET NO. AVSI-0034 SERIAL NO. 10/798,896
PATENT FILED: March 11, 2004

IN THE SPECIFICATION:

Please amend paragraph [0162] as follows:

[0162] Additional experiments were done to determine the effects of IGF-I plasmid mediated supplementation using a construct that stimulates the secretion of the transgene product into the general circulation on MyoD myogenin expression after a nerve injury. The sciatic nerve of ICR-I female mice was crushed mid thigh. Afterwards, 120 µg of pSP-IGF-I-GH3'UTR (pAV2002 - SEQID No.: 2), diluted in distilled water was injected in the tibialis anterior in a volume of 30 µl. The muscle was then electroporated at 220V/cm, 20 msec, and 3 pulses, positive and reverse polarity, each. In control mice, 30 µl of distilled water was injected into injured muscle and electroporated as above. After 3 days, the muscle of IGF-I and waterinjected mice was analyzed with CELISA. The results shown in Figure 6 indicate that IGF-I plasmid mediated supplementation using a construct that stimulates the secretion of the transgene product into the general circulation does not affect myogenin expression in the treated muscle.